



Delaware Division of Public Health
Community-Based Naloxone Access Program
Intra-nasal Naloxone Distribution and Administration
Standing Order

Effective: March 4th, 2024- June 30th, 2025



*DELAWARE HEALTH
AND SOCIAL SERVICES*
Division of Public Health

Community-Based Naloxone Access Program (CBNAP)

Intra-nasal Naloxone Distribution and Administration

STANDING ORDER

Target Audience

Approved for use by the Community-Based Naloxone Access Program's participating programs and agencies and participating pharmacies.

INDICATIONS: Naloxone (naloxone hydrochloride) is indicated for reversal of opioid overdose in the setting of respiratory depression (slow breathing) or no breathing (apnea), or unresponsiveness. It may be delivered intra-nasally with the use of a mucosal atomizer device.

This protocol will allow programs/agencies/pharmacies to dispense intra-nasal naloxone kits to overdose responders for the treatment of persons who are suspected to have overdosed on opioids.

Order to dispense:

- This standing order authorizes approved Community-Based programs and participating pharmacies to distribute intra-nasal naloxone kits.
- This standing order authorizes approved Community-Based programs to maintain supplies of intra-nasal naloxone kits for the purpose of distributing them as part of the Naloxone Access Program.
- Community-Based programs must make training on responding to overdose situations and naloxone administration available and easily accessible to anyone seeking a kit.
 - Intra-nasal naloxone kits must contain written administration instructions.
 - Whenever feasible, programs should directly provide training on overdose response and naloxone administration to persons seeking naloxone kits. This may be in-person or online training.
 - At a minimum, programs must provide information to kit recipients on how to access training (in-person or online) on overdose response and naloxone administration. Programs should strongly encourage recipients to undergo training.
- Pharmacists should consider offering training and intra-nasal naloxone kits to patients who have been prescribed 50 or more morphine milligram equivalents (MME) per day.

Intra-nasal Naloxone kits must contain the following at a minimum:

- Two naloxone hydrochloride (4 mg/0.1 mL) pre-filled intra-nasal spray applicators (labeled to meet board of pharmacy standards) .
- Product-specific written instructions, including step-by-step instructions on administering naloxone intra-nasally
- Information on how to obtain training on naloxone administration (including in-person and/or online training)
- Delaware Overdose Guidance document (available at <https://www.dhss.delaware.gov/dhss/dph/standingorders.html>)

Minimum content of training

Training made available by Community-based programs to naloxone kit recipients must meet the requirement of *CBNAP Opioid Overdose Responder Training* (see “definitions” below). This includes both training provided by the program and training to which the program refers naloxone kit recipients. This training must (at the minimum) cover certain topics to guide opioid overdose responders’ actions and/or provide required knowledge. Topics that must be covered include:

- Recognition of the signs and symptoms of overdose such as slow breathing, or no breathing and/or unresponsiveness.
- Early activation of emergency medical services (calling for help) by dialing 911.
- Step by step instructions on administration of intra-nasal naloxone.
- Early initiation of CPR (cardiopulmonary resuscitation) for those who have CPR training.
- Being prepared to provide CPR under the direction of 911 dispatcher (for those who may not have CPR training)
- Repeat administration of naloxone if there is no change in breathing or responsiveness 3-5 minutes after initial naloxone administration.
- Remaining with the person who overdosed until help arrives in the form of a medical professional.
- Administering naloxone without delay if there is no information about whether the person is allergic or not (not delaying administration due to unknown allergy history)
- Not administering naloxone to a person who is known to be allergic to naloxone
- Warning about the potential of naloxone to cause rapid opiate withdrawal (include information on symptoms of rapid withdrawal).
- Information that certain overdose situations that may require higher doses of naloxone

for reversal than dispensed in the kits. (Underscoring the importance of calling important to call 911 early in case the person needs more than you have on hand.

Refills

Additional naloxone intra-nasal spray kits may be provided to opioid overdose responders. With each refill, responders must be provided the same opportunities to get training as with the initial dispensing.

Tracking

Community-based programs/agencies/partners approved to dispense will maintain documentation on the following at the minimum:

- Date of dispensing
- Whether or not training was provided, and if so, number of persons trained.
- Expiration date of dispensed preparation
- Self-reported zip code of kit destination (or zip code distributed in if recipient declined to provide)
- Notification (by agency to DHSS) of expiring kits
- Number of refills (where applicable)
- Naloxone uses and outcome (if reported by recipients).

Participating pharmacies will maintain these records with prescriptions filled under these standing orders.

This tracking information shall be made available to the CBNAP Program Coordinator from the CBNAP Program Liaisons as requested.

Storage

Store in the blister provided. Store at controlled room temperature at 15-25C (59-77F). Excursions are permitted up to 40C (104F). Do not freeze. Protect from light while stored.

Definitions

Community-Based Naloxone Access Program (CBNAP)

A program approved by Delaware Health and Social Services, Division of Public Health (DPH) to provide overdose response education and access to naloxone distribution services in accordance with these standing orders and program agreements. DPH has designated the Division of Substance Abuse and Mental Health (DSAMH) as the approved program for the state.

CBNAP Opioid Overdose Responder Training

An approved educational program which includes at a minimum: overdose prevention

techniques, recognizing signs and symptom of overdose; calling 911, airway and breathing assessment; rescue breathing, naloxone storage, carrying and administration, post-overdose follow-up and care. This training may be provided by community-based classes, point-of-distribution events, online videos, or by direct instruction from a pharmacist or other healthcare provider.

CBNAP Program Coordinator:

An employee of the state, appointed by the Director of the Division of Public Health to oversee and coordinate the implementation, data collection, and monitoring of the CBNAP program and approved Community-Based training programs.

CBNAP Program Liaison:

An employee of the partnering agency, program, or pharmacy designated to serve as a single point of contact for coordination and communication with the CBNAP Program Coordinator.

Statewide Standing Order Authorization

This policy and procedure shall remain in effect from March 4th, 2024 to June 30th 2025



2/27/24

Awele Maduka-Ezeh MD MPH PhD

Medical Director Delaware Division of Public Health

